At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 186 enrolled
Drug / intervention
citalopram +1 moredrug
Likely dose
citalopram 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease
In Brief
A Phase 3 clinical trial evaluating citalopram and placebo for Alzheimer's Disease and Agitation. Completed, enrolled 186 participants across 8 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease, Agitation
CountriesCanada, United States
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJul 2009
Primary CompletionSep 2013
TodayJul 2026
First PostedMay 12, 2009
Enrollment StartJul 1, 2009
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 17.1 years ago
Interventions
citalopramdrug
target dose 30mg daily for 9 weeks
placebodrug
daily for 9 weeks